Matches in SemOpenAlex for { <https://semopenalex.org/work/W3021563531> ?p ?o ?g. }
- W3021563531 endingPage "119" @default.
- W3021563531 startingPage "109" @default.
- W3021563531 abstract "Patients with metastatic angiosarcoma undergoing chemotherapy, radiation, and/or surgery experience a median progression free survival of less than 6 months and a median overall survival of less than 12 months. Given the aggressive nature of this cancer, angiosarcoma clinical responses to chemotherapy or targeted therapeutics are generally very poor. Inhibition of beta adrenergic receptor (β-AR) signaling has recently been shown to decrease angiosarcoma tumor cell viability, abrogate tumor growth in mouse models, and decrease proliferation rates in preclinical and clinical settings. In the current study we used cell and animal tumor models to show that β-AR antagonism abrogates mitogenic signaling and reduces angiosarcoma tumor cell viability, and these molecular alterations translated into patient tumors. We demonstrated that non-selective β-AR antagonists are superior to selective β-AR antagonists at inhibiting angiosarcoma cell viability. A prospective analysis of non- selective β-AR antagonists in a single arm clinical study of metastatic angiosarcoma patients revealed that incorporation of either propranolol or carvedilol into patients' treatment regimens leads to a median progression free and overall survival of 9 and 36 months, respectively. These data suggest that incorporation of non-selective β-AR antagonists into existing therapies against metastatic angiosarcoma can enhance clinical outcomes." @default.
- W3021563531 created "2020-05-13" @default.
- W3021563531 creator A5007607352 @default.
- W3021563531 creator A5009790161 @default.
- W3021563531 creator A5010387252 @default.
- W3021563531 creator A5011364716 @default.
- W3021563531 creator A5018849701 @default.
- W3021563531 creator A5021450775 @default.
- W3021563531 creator A5023036166 @default.
- W3021563531 creator A5027100817 @default.
- W3021563531 creator A5034855764 @default.
- W3021563531 creator A5041594080 @default.
- W3021563531 creator A5049136467 @default.
- W3021563531 creator A5049317879 @default.
- W3021563531 creator A5055710878 @default.
- W3021563531 creator A5065562810 @default.
- W3021563531 creator A5070645244 @default.
- W3021563531 creator A5070712973 @default.
- W3021563531 creator A5077094251 @default.
- W3021563531 creator A5078916422 @default.
- W3021563531 date "2018-04-29" @default.
- W3021563531 modified "2023-10-15" @default.
- W3021563531 title "Non-selective beta blockers inhibit angiosarcoma cell viability and increase progression free- and overall-survival in patients diagnosed with metastatic angiosarcoma" @default.
- W3021563531 cites W1135618184 @default.
- W3021563531 cites W1485843004 @default.
- W3021563531 cites W1494448598 @default.
- W3021563531 cites W1504344127 @default.
- W3021563531 cites W1509291382 @default.
- W3021563531 cites W1536751072 @default.
- W3021563531 cites W1559201260 @default.
- W3021563531 cites W1597546967 @default.
- W3021563531 cites W1743944563 @default.
- W3021563531 cites W1797398930 @default.
- W3021563531 cites W1906872188 @default.
- W3021563531 cites W1912803480 @default.
- W3021563531 cites W1947924801 @default.
- W3021563531 cites W1963528534 @default.
- W3021563531 cites W1963642761 @default.
- W3021563531 cites W1963910752 @default.
- W3021563531 cites W1974008746 @default.
- W3021563531 cites W1977455950 @default.
- W3021563531 cites W1987397258 @default.
- W3021563531 cites W1987492859 @default.
- W3021563531 cites W1991374291 @default.
- W3021563531 cites W1997561962 @default.
- W3021563531 cites W2002235642 @default.
- W3021563531 cites W2006955905 @default.
- W3021563531 cites W2009811269 @default.
- W3021563531 cites W2018772561 @default.
- W3021563531 cites W2023766293 @default.
- W3021563531 cites W2025607005 @default.
- W3021563531 cites W2026683311 @default.
- W3021563531 cites W2026777357 @default.
- W3021563531 cites W2029855461 @default.
- W3021563531 cites W2031937031 @default.
- W3021563531 cites W2042886026 @default.
- W3021563531 cites W2061050183 @default.
- W3021563531 cites W2062318540 @default.
- W3021563531 cites W2068852777 @default.
- W3021563531 cites W2075942814 @default.
- W3021563531 cites W2076033933 @default.
- W3021563531 cites W2079248475 @default.
- W3021563531 cites W2079273956 @default.
- W3021563531 cites W2080347660 @default.
- W3021563531 cites W2083977403 @default.
- W3021563531 cites W2086132487 @default.
- W3021563531 cites W2096902150 @default.
- W3021563531 cites W2097080296 @default.
- W3021563531 cites W2107270877 @default.
- W3021563531 cites W2118147608 @default.
- W3021563531 cites W2118880688 @default.
- W3021563531 cites W2123338449 @default.
- W3021563531 cites W2135451637 @default.
- W3021563531 cites W2136627464 @default.
- W3021563531 cites W2139731996 @default.
- W3021563531 cites W2142193119 @default.
- W3021563531 cites W2144530818 @default.
- W3021563531 cites W2146651717 @default.
- W3021563531 cites W2150740158 @default.
- W3021563531 cites W2163758556 @default.
- W3021563531 cites W2169876742 @default.
- W3021563531 cites W2170973522 @default.
- W3021563531 cites W2171415105 @default.
- W3021563531 cites W2171487703 @default.
- W3021563531 cites W2177345733 @default.
- W3021563531 cites W2286357201 @default.
- W3021563531 cites W2315508596 @default.
- W3021563531 cites W2341539059 @default.
- W3021563531 cites W2472708295 @default.
- W3021563531 cites W2514175877 @default.
- W3021563531 cites W2525918371 @default.
- W3021563531 cites W2528320990 @default.
- W3021563531 cites W2530867754 @default.
- W3021563531 cites W2535549547 @default.
- W3021563531 cites W2539836675 @default.
- W3021563531 cites W2554825308 @default.
- W3021563531 cites W2560646828 @default.
- W3021563531 cites W2566106732 @default.